Name: | Tissue Engineering & Regenerative Medicine International Society |
---|---|
Link: | http://termis.org/ |
Description: | To accomplish its mission, the Society brings together the international community of persons engaged or interested in the field of tissue engineering and regenerative medicine and promotes education and research within the field of tissue engineering and regenerative medicine through regular meetings, publications and other forms of communication. The Society also serves as an international forum to promote the informed discussion of challenges and therapeutic benefits of the application of tissue engineering and regenerative medicine technologies. Most importantly, the Society is committed to bringing you closer to key professionals to support your mutual understanding of the field, accelerate your research in the field and to enable you to contribute to the ultimate care of patients in this very important way. To affect this interchange of information, the Society has endorsed the journal, Tissue Engineering, as its official publication and has negotiated a reduced subscription rate for members of the TERMIS. In addition, the TERMIS publishes a quarterly newsletter for its members to keep them abreast of developments in the field. The TERMIS World Congress Meeting will be held every three years. In the interim years the Continental Chapters will host annual meetings to promote tissue engineering and regenerative medicine research regionally. Your participation in the TERMIS will be rewarding for you and enriching for the Society's existing members. |
Gate2Biotech - Biotechnology Portal - All Czech Biotechnology information in one place.
ISSN 1802-2685
This website is maintained by: CREOS CZ
© 2006 - 2024 South Bohemian Agency for Support to Innovative Enterprising (JAIP)
Interesting biotechnology content:
Biotech - International biotech science
Biotechnology events - Database of international biotechnology events.
Suspended animation drug could buy time in medical emergencies
Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials